Drotaverine mechanismm of action and uses side effects
Reading File
Finding Sources
Searching PubMed
drotaverine
Searching the Web
drotaverine prescribing information mechanism contraindications adverse effects
Drotaverine is a non-anticholinergic antispasmodic drug. It relieves pain caused by spasm of smooth muscle, but it is not a painkiller for all types of pain.
Mechanism of action
- It selectively inhibits phosphodiesterase-4 (PDE4).
- PDE4 inhibition prevents breakdown of cyclic AMP (cAMP).
- Increased intracellular cAMP lowers available calcium for contraction within smooth-muscle cells.
- The result is relaxation of smooth muscle in the gastrointestinal, biliary, urinary, and uterine tracts.
- Unlike atropine-like antispasmodics, it has no significant anticholinergic action, so dry mouth, blurred vision, and urinary retention are generally less prominent.
Yamada's Textbook of Gastroenterology describes drotaverine as a selective PDE4 inhibitor without anticholinergic effects. Its mechanism is also summarized by DrugBank.
Uses
Drotaverine may be used for symptomatic relief of smooth-muscle spasm, including:
- Intestinal cramps/colic, including spasm associated with irritable bowel syndrome
- Biliary colic and gallbladder-related spasm
- Renal or ureteric colic as an adjunct for cramp-like pain
- Dysmenorrhea - painful menstrual cramps
- Spasm related to some genitourinary or gynecologic procedures
It treats the spasm and cramping, not the underlying cause. For example, severe abdominal pain, fever, jaundice, vomiting, or blood in urine needs medical assessment rather than repeated self-treatment.
Side effects
Usually mild, but can include:
| System | Possible effects |
|---|---|
| Nervous system | Headache, dizziness, vertigo, insomnia |
| Gastrointestinal | Nausea, vomiting, constipation |
| Cardiovascular | Palpitations, low blood pressure, rarely fainting |
| Allergy | Rash, itching, hives, swelling of face/lips, rarely severe hypersensitivity |
Precautions
- Avoid or use only under clinician advice in severe liver, kidney, or heart disease.
- Use cautiously if prone to low blood pressure, dizziness, or fainting.
- Pregnancy and breastfeeding use should be decided by a clinician, because indications and product approvals differ by country.
- Seek urgent help for facial swelling, breathing difficulty, fainting, or a rapid/irregular heartbeat.
Drotaverine is not licensed or routinely available in every country, so use should follow the specific local product information and a clinician's advice.
Can be used in ckd stage 2 and liver cirrhosis patient?
Reading File
Finding Sources
Searching PubMed
drotaverine hepatic impairment renal impairment
Searching the Web
drotaverine Summary of Product Characteristics hepatic renal impairment contraindicated severe hepatic impairment
Reading Web Page
https://products.pharmacyboardkenya.org/uploads/CTD10090_Spa…
CKD stage 2 alone: Drotaverine is generally not automatically contraindicated in mild kidney impairment such as CKD stage 2, but it should be prescribed with awareness of blood pressure and overall kidney status. Product information typically lists severe renal impairment as a contraindication or reason to avoid use.
Liver cirrhosis: This needs much more caution. Drotaverine is metabolized in the liver, and many product labels advise avoiding it in severe hepatic impairment. Therefore:
- Compensated/mild cirrhosis: may sometimes be used only if the prescribing clinician judges it appropriate, usually for a short course.
- Decompensated or severe cirrhosis: avoid unless a hepatologist or treating physician specifically recommends it. Features include ascites, encephalopathy, variceal bleeding, marked jaundice, or poor synthetic function such as high INR/low albumin.
Do not self-start it for abdominal pain in cirrhosis. New or worsening abdominal pain can signal ascites infection, biliary obstruction, gastrointestinal bleeding, pancreatitis, or other problems that need assessment.
Very important: check whether the tablet is drotaverine alone or a combination such as drotaverine + mefenamic acid/diclofenac. Avoid NSAID-containing combinations unless the liver/kidney clinician specifically prescribes them. NSAIDs can precipitate kidney injury, fluid retention/ascites, gastrointestinal bleeding, and worsening liver decompensation. A product monograph for drotaverine plus mefenamic acid confirms liver metabolism of drotaverine and warns that renal and liver function require monitoring in toxicity contexts, while the NSAID adds separate risks. Product information
Also avoid or use particular caution if the patient has low blood pressure, dizziness, fainting, or significant heart disease, because drotaverine can lower blood pressure.
For a cirrhosis patient, the safe answer should be based on the Child-Pugh class, current creatinine/eGFR, blood pressure, ascites status, and the exact product.
This is a shared conversation. Sign in to Orris to start your own chat.